


GUERNSEY STATUTORY INSTRUMENT

2010 NO. 22



The Misuse of Drugs (Modification) Order, 2010

Made 23 February, 2010
Coming into operation 8 March, 2010
Laid before the States , 2010

THE HEALTH AND SOCIAL SERVICES DEPARTMENT, in exercise of the powers conferred on it by sections 1(2), 6, 9, 21 and 30 of the Misuse of Drugs (Bailiwick of Guernsey) Law, 1974^a, section 1(2) of the Misuse of Drugs (Amendment) (Bailiwick of Guernsey) Law, 2000^b and all other powers enabling it in that behalf, hereby makes the following order: -

Substitution of First Schedule to the 1974 Law.

1. The Misuse of Drugs (Bailiwick of Guernsey) Law, 1974 is amended by substituting, for the First Schedule to that Law, the schedule set out in Schedule 1 to this Order.

Insertion of new sections 3A and 3B into the 1997 Ordinance.

2. Immediately after section 3 of the Misuse of Drugs (Bailiwick of Guernsey) Ordinance, 1997^c ("the 1997 Ordinance"), insert the following sections:

^a Ordres en Conseil Vol. XXIV, p. 273; amended by Vol. XXVIII, p. 307; Vol. XXXI, pp. 47 and 278; Orders in Council No. XIII of 1991; No. XVI of 1995; Nos. III and VII of 2000; Nos. IV and XIII of 2006; Recueil d'Ordonnances Tome XXIX, p 406; G.S.I. 2008 No. 20.

^b Order in Council No. III of 2000.

^c Recueil d'Ordonnances Tome XXVII, p. 247; amended by G.S.I. 2004 No. 4, 2006 No. 42 and 2008 No. 20.

"Exceptions for fungi which contain psilocin or an ester of psilocin.

3A. (1) Section 4(1) of the Law (which prohibits the possession of controlled drugs) shall not have effect in relation to a fungus (of any kind) which contains psilocin or an ester of psilocin where that fungus—

- (a) is growing uncultivated,
- (b) is picked by a person already in lawful possession of it for the purpose of delivering it as soon as is reasonably practicable into the custody of a person lawfully entitled to take custody of it and it remains in the former person's possession for and in accordance with that purpose,
- (c) is picked for either of the purposes specified in subsection (2) and is held for and in accordance with the purpose specified in subsection (2)(b), either by the person who picked it or by another person, or
- (d) is picked for the purpose specified in subsection (2)(b) and is held for and in accordance with the purpose specified in subsection (2)(a), either by the person who picked it or by another person.

(2) The purposes referred to in subsection (1)(c) and (d) are—

- (a) the purpose of delivering the fungus as soon as is reasonably practicable into the custody of a person lawfully entitled to take custody of it, and
- (b) the purpose of destroying the fungus as soon as is reasonably practicable.

Exceptions for gamma-butyrolactone and 1,4-butanediol.

3B. (1) Nothing in section 2(1) (which prohibits the importation and exportation of controlled drugs), section 3(1) (which prohibits the production and supply of controlled drugs) or section 4(1) (which prohibits the possession of controlled drugs) of the Law shall have effect in relation to gamma-butyrolactone or 1,4-butanediol except where a person imports, exports, produces, supplies or offers to supply either substance, or has either substance in his possession, knowing or believing that it will be used for the purpose of human ingestion other than as a flavouring in food, whether by himself or another person.

(2) In this section, references to gamma-butyrolactone and 1,4-butanediol include—

- (a) any stereoisomeric form of gamma-butyrolactone or 1,4-butanediol,
- (b) any salt of gamma-butyrolactone, 1,4-butanediol or of a substance specified in paragraph (a), and
- (c) any preparation or other product containing gamma-butyrolactone, 1,4-

butanediol or a substance specified in paragraph (a) or (b).”.

Substitution of Schedules 1 to 4 to the 1997 Ordinance.

3. The 1997 Ordinance is amended by substituting, for Schedules 1, 2, 3 and 4 respectively, the schedules set out in Schedule 2 to this Order.

Consequential amendments.

4. (1) The Misuse of Drugs (Modification) Order, 2003^d is amended by revoking article 5.

(2) The Misuse of Drugs (Modification) Order, 2008^e is amended by revoking articles 1 and 2 (2) and (3) and Schedules 1, 2 and 3.

Interpretation.

5. The provisions of the Interpretation (Guernsey) Law, 1948^f apply to the interpretation of this Order as they apply to a Guernsey enactment.

Citation.


6. This Order may be cited as the Misuse of Drugs (Modification) Order, 2010.

Commencement.

7. This Order comes into force on the 8th of March, 2010.

^d G.S.I. 2003 No. 5.
^e G.S.I. 2008 No. 20.
^f Ordres en Conseil Vol. XIII, p. 355.

Dated this 23rd day of February 2010.

A handwritten signature in black ink, appearing to read 'A. R. Le Lievre', followed by a horizontal dotted line.

Deputy A. R. LE LIEVRE

Deputy Minister of the Health and Social Services Department

For and on behalf of the Department.

EXPLANATORY NOTE

(This note is not part of the Order)

This Order replaces the First Schedule to the Misuse of Drugs (Bailiwick of Guernsey) Law, 1974, with a new Schedule.

This Order adds synthetic cannabinoid receptor agonists to Part II of the Schedule which specifies drugs which are subject to control as Class B drugs under the Law.

In addition, this Order adds gamma-butyrolactone (GBL), 1,4-butanediol (1,4-BD), 15 anabolic steroids, two non-steroidal agents, Oripavine, 1-benzylpiperazine (BZP) and a group of substituted piperazines to Part III of the Schedule which specifies drugs which are subject to control as Class C drugs under the Law.

The Order also updates Schedules 1, 2 and 4 to the Misuse of Drugs (Bailiwick of Guernsey) Ordinance, 1997 to ensure that the above drugs are included.

This Order also corrects a number of minor erroneous inclusions, omissions and spelling mistakes which had been made in previous Schedules.

SCHEDULE 1

Article 1

"FIRST SCHEDULE

Section 1

CONTROLLED DRUGS

PART I

CLASS A DRUGS

1. The following substances and products –

- (a) Acetorphine
- Alfentanil
- Allylprodine
- Alphacetylmethadol
- Alphameprodine
- Alphamethadol
- Alphaprodine
- Anileridine
- Benzethidine
- Benzylmorphine (3-benzylmorphine)
- Betacetylmethadol
- Betameprodine
- Betamethadol
- Betaprodine
- Bezitramide
- Bufotenine
- Cannabinol, except where contained in cannabis or cannabis resin
- Cannabinol derivatives
- Carfentanil
- Clonitazene
- Coca leaf
- Cocaine
- Desomorphine
- Dextromoramide

Diamorphine
Diampromide
Diethylthiambutene
Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid)
Dihydrocodeinone *O*-carboxymethyloxime
Dihydroetorphine
Dihydromorphine
Dimenoxadole
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl butyrate
Diphenoxylate
Dipipanone
Drotebanol (3,4-dimethoxy-17-methylmorphinan-6 β ,14-diol)
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
Ethylmethylthiambutene
Eticyclidine
Etonitazene
Etorphine
Etoxidine
Etryptamine
Fentanyl
Fungus (of any kind) which contains psilocin or an ester of psilocin
Furethidine
Hydrocodone
Hydromorphinol
Hydromorphone
Hydroxypethidine
Isomethadone
Ketobemidone
Levomethorphan
Levomoramide
Levophenacyl morphan
Levorphanol
Lofentanil
Lysergamide
Lysergide and other *N*-alkyl derivatives of lysergamide
Mescaline
Metazocine
Methadone
Methadyl acetate

Methylamphetamine
Methyldesorphine
Methyldihydromorphine (6-methyldihydromorphine)
Metopon
Morpheridine
Morphine
Morphine methobromide, morphine *N*-oxide and other pentavalent
nitrogen morphine derivatives
Myrophine
Nicomorphine (3,6-dinicotinoyl-morphine)
Noracymethadol
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Opium, whether raw, prepared or medicinal
Oxycodone
Oxymorphone
Pethidine
Phenadoxone
Phenampramide
Phenazocine
Phencyclidine
Phenomorphane
Phenoperidine
Piminodine
Piritramide
Poppy-straw and concentrate of poppy-straw
Proheptazine
Propriodine (1-methyl-4-phenylpiperidine-4-carboxylic acid isopropyl
ester)
Psilocin
Racemethorphan
Racemoramide
Racemorphan
Remifentanyl
Rolicyclidine
Sufentanyl
Tenocyclidine
Thebacon
Thebaine
Tilidate
Trimeperidine

4-Bromo-2, 5-dimethoxy- α -methylphenethylamine
 4-Cyano-2-dimethylamino-4,4-diphenylbutane
 4-Cyano-1-methyl-4-phenylpiperidine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
 2,5-Dimethoxy- α ,4-dimethylphenethylamine
 1-diphenylpropanecarboxylic acid
 N-Hydroxy-tenamphetamine
 1-Methyl-4-phenylpiperidine-4-carboxylic acid
 2-Methyl-3-morpholino-1,1-diphenylpropanecarboxylic acid
 4-Methyl-aminorex
 4-Phenylpiperidine-4-carboxylic acid ethyl ester;

(b) any compound (not being a compound specified in subparagraph (a)) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c) the following phenethylamine derivatives –

Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
 2-Amino-1(3,4-dimethoxyphenyl)ethanol
 Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 4-Bromo- β , 2,5-trimethoxyphenethylamine
 N-(4-sec-Butylthio-2,5dimethoxyphenethyl)hydroxylamine
 Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)ethylamine
 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)-1-methylethylamine
 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
 2-(1,4-Dimethoxy-2-naphthyl)ethylamine
 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
 Dimethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
 4-Iodo-2,5-dimethoxy- α -methylphenethyl(dimethyl)amine
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl) ethylamine
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 β -Methoxy-3,4-methylenedioxyphenethylamine
 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
 2-(α -Methyl-3,4-methylenedioxyphenethylamino)ethanol
 α -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-*N*-(α -Methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-*N*-(α -Methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 α -Methyl-4-(methylthio)phenethylamine
 β ,3,4,5-Tetramethoxyphenethylamine
 β ,2,5-Trimethoxy-4-methylphenethylamine;

- (d) any compound (not being methoxyphenamine or a compound specified in subparagraph (a)) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α -methylphenethylamine, an *N*-alkyl- α -methylphenethylamine, α -ethylphenethylamine, or an *N*-alkyl- α -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound specified in subparagraph (a)) structurally derived from fentanyl by modification in any of the following ways –
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group; or

- (vi) by replacement of the *N*-propionyl group by another acyl group;
- (f) any compound (not being a compound specified in subparagraph (a)) structurally derived from pethidine by modification in any of the following ways –
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group; or
 - (v) by formation of an *N*-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1 , not being dextromethorphan or dextrorphan.
 3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in Part II.
 4. Any salt of a substance specified in any of paragraphs 1 to 3.
 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4.
 6. Any preparation designed for administration by injection which includes a substance or product specified in any of paragraphs 1 to 3 of Part II.

PART II

CLASS B DRUGS

1. The following substances and products –

- (a) Acetyldihydrocodeine
 Amphetamine
 Cannabis and cannabis resin
 Codeine
 Dihydrocodeine
 Ethylmorphine (3-ethylmorphine)
 Glutethimide
 Lefetamine
 Mecloqualone
 Methaqualone
 Methcathinone
 α -Methylphenethylhydroxylamine
 Methylphenidate
 Methylphenobarbitone
 Nicocodine
 Nicodicodine (6-nicotinoyldihydrocodeine)
 Norcodeine
 Pentazocine
 Phenmetrazine
 Pholcodine
 Propiram
 Zipeprol;
- (b) any 5, 5 disubstituted barbituric acid;
- (c) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol
 [9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate
 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[*c*]chromen-1-ol
 Nabilone;
- (d) Any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring

to any extent and whether or not substituted in the naphthyl ring to any extent;

- (e) Any compound structurally derived from 3-(naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
 - (f) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not substituted in the naphthyl ring to any extent;
 - (g) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
 - (h) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.
2. Any stereoisomeric form of a substance specified in paragraph 1 of this Part.
 3. Any salt of a substance specified in paragraph 1 or 2 of this Part.
 4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3 of this Part, not being a preparation falling within paragraph 6 of Part I.
 5. Any ester or ether of a substance specified in paragraph 1(c) of this Part.

PART III

CLASS C DRUGS

1. The following substances –

(a) Alprazolam
Aminorex
Benzphetamine
Bromazepam
Brotizolam
Buprenorphine
Camazepam
Cathine
Cathinone
Chlordiazepoxide
Chlorphentermine
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Dextropropoxyphene
Diazepam
Diethylpropion
Estazolam
Ethchlorvynol
Ethinamate
N-Ethylamphetamine
Ethyl loflazepate
Fencamfamin
Fenethylamine
Fenproporex
Fludiazepam
Flunitrazepam
Flurazepam
Gamma-butyrolactone
Halazepam
Haloxazolam
4-Hydroxy-n-Butyric Acid
Ketamine
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Mazindol
Medazepam
Mefenorex

Mephentermine
Meprobamate
Mesocarb
Methyprylone
Midazolam
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Phendimetrazine
Phentermine
Pinazepam
Pipradrol
Prazepam
Pyrovalerone
Temazepam
Tetraazepam
Triazolam
Zolpidem;

- (b) 5 α -Androstane-3,17-diol
Androst-4-ene-3,17-diol
1-Androstenediol
1-Androstenedione
4-Androstene-3,17-dione
5-Androstenedione
5-Androstene-3, 17-diol
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone
Boldione
Bolenol
Bolmantalate
1,4-Butanediol
Calusterone
4-Chloromethandienone
Clostebol
Danazol

Desoxymethyltestosterone
Drostanolone
Enestebol
Eptiostanol
Ethyloestrenol
Fluoxymesterone
Formebolone
Furazabol
Gestrinone
3-Hydroxy-5 α -androstan-17-one
Mebolazine
Mesabolone
Mestanolone
Mesterolone
Methandienone
Methandriol
Methenolone
Methyltestosterone
Metribolone
Mibolerone
Nandrolone
19-Norandrostenedione
19-Nor-4-Androstene-3,17-dione
19-Nor-5-Androstene-3,17-diol
19-Norandrosterone
Norboletone
Norclostebol
Norethandrolone
19-Noretiocholanolone
Oripavine
Ovandroton
Oxandrolone
Oxabolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
Prostanozol
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol

Stenbolone
Testosterone
Tetrahydrogestrinone
Thiomesterone
Trenbolone;

(c) Any compound (not being Trilostane or a compound specified in paragraph 1 of this Part) structurally derived from 17- hydroxyandrostane-3-one or from 17-hydroxyestrane-3-one by modification in any of the following ways –

- (i) by further substitution at position 17 by a methyl or ethyl group;
- (ii) by substitution to any extent at one or more of the positions 1,2,4,6,7,9,11 or 16, but at no other position;
- (iii) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring; or
- (iv) by fusion of ring A with a heterocyclic system;

(d) 1-benzylpiperazine or any compound structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in either of the following ways-

- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups; or
- (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl groups;

(e) Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph (b) or described in paragraph (c) of this Part;

(f) The following substances –

Chorionic gonadotrophin (HCG)
Clenbuterol
Non-human chorionic gonadotrophin (HCG)
Somatotropin
Somatrem

Somatropin
Zeranol
Zilpaterol.

2. Any stereoisomeric form of a substance specified in paragraph 1 of this Part, not being phenylpropanolamine.
3. Any salt of a substance specified in paragraph 1 or 2 of this Part.
4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3 of this Part.

PART IV

MEANING OF CERTAIN EXPRESSIONS USED IN THIS SCHEDULE

For the purposes of this Schedule the following expressions have the meanings assigned to them:-

"cannabinol derivatives" means the following substances, except where contained in cannabis or cannabis resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives,

"coca leaf" means the leaf of any plant of the genus *Erythroxylon* from whose leaves cocaine can be extracted either directly or by chemical transformation,

"concentrate of poppy-straw" means the material produced when poppy-straw has entered into a process for the concentration of its alkaloids,

"medicinal opium" means raw opium which has undergone the process necessary to adapt it for medicinal use in accordance with the requirements of the British Pharmacopoeia, whether it is in the form of powder or is granulated or is in any other form, and whether it is or is not mixed with neutral substances,

"opium poppy" means the plant of the species *Papaver somniferum*;
L,

"poppy straw" means all parts, except the seeds, of the opium poppy after mowing, and

"raw opium" includes powdered or granulated opium but does not include medicinal opium."

SCHEDULE 2

Article 3

“SCHEDULE 1

Section 3

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF SECTIONS 12, 13, 14, 16, 17, 18, 21, 23 and 24

1. The following substances and products —

- (a) Bufotenine
- Cannabinol
- Cannabinol derivatives, not being dronabinol or its stereoisomers
- Cannabis and cannabis resin
- Cathinone
- Coca leaf
- Concentrate of poppy-straw
- [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
- 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol
- Eticyclidine
- Fungus (of any kind) which contains psilocin or an ester of psilocin
- [9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl] oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate
- 9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[*c*]chromen-1-ol;
- Lysergamide
- Lysergide and other N-alkyl derivatives of lysergamide
- Mescaline
- Methcathinone
- Psilocin
- Raw opium
- Rolicyclidine
- Tenocyclidine
- 4-Bromo-2,5-dimethoxy- α -methylphenethylamine
- N,N-Diethyltryptamine
- N,N-Dimethyltryptamine

2,5-Dimethoxy- α ,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex;

- (b) any compound (not being a compound specified in subparagraph (a)) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) the following phenethylamine derivatives –

Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo- β ,2,5-trimethoxyphenethylamine
N-(4-*sec*-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 $\alpha\alpha$ -Dimethyl-3,4-methylenedioxyphenethylamine
 $\alpha\alpha$ -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy- α -methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-
methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-
methylethylamine
2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-
methylethylamine
 β -Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(α -Methyl-3,4-methylenedioxyphenethylamino)ethanol

α -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 α -Methyl-4-(methylthio)phenethylamine
 β ,3,4,5-Tetramethoxyphenethylamine
 β ,2,5-Trimethoxy-4-methylphenethylamine;

- (d) any compound (not being methoxyphenamine or a compound specified in subparagraph (a)) structurally derived from phenethylamine, an *N*-alkylphenethylamine, a-methylphenethylamine, an *N*-alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an *N*-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways —
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group; or
 - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (f) any compound (not being a compound specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways —
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

- (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group; or
 - (v) by formation of an *N*-oxide or of a quaternary base;
- (g) 1-benzylpiperazine or any compound (not being a compound specified in Schedule 4) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in either of the following ways —
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups; or
 - (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl groups;
- (h) any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (i) any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (j) any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (k) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

- (l) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.
2. Any stereoisomeric form of a substance specified in paragraph 1.
3. Any ester or ether of a substance specified in paragraph 1 or 2.
4. Any salt of a substance specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

SCHEDULE 2

Sections 5, 6, 7, 9,
17(1)(b), 19, 24(4)

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF SECTIONS 12, 13, 14, 16, 17, 18, 19, 21, 23 and 24

1. The following substances and products —

Acetorphine
Alfentanil
Allylprodine
Alphacetylmethadol
Alphameprodine
Alphamethadol
Alphaprodine
Anileridine
Benzethidine
Benzylmorphine (3-benzylmorphine)
Betacetylmethadol
Betameprodine
Betamethadol
Betaprodine

Bezitramide
Carfentanil
Clonitazene
Cocaine
Desomorphine
Dextromoramide
Diamorphine
Diampromide
Diethylthiambutene
Difenoxin
Dihydrocodeinone O-carboxymethyloxime
Dihydroetorphine
Dihydromorphine
Dimenoxadole
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl butyrate
Diphenoxylate
Dipipanone
Dronabinol
Drotebanol
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
Ethylmethylthiambutene
Etonitazene
Etorphine
Etoxidine
Fentanyl
Furethidine
Hydrocodone
Hydromorphanol
Hydromorphone
Hydroxypethidine
Isomethadone
Ketobemidone
Levomethorphan
Levomoramide
Levophenacilmorphan
Levorphanol
Lofentanil
Medicinal opium
Metazocine
Methadone

Methadyl acetate
Methyldesorphine
Methyldihydromorphine (6-methyldihydromorphine)
Metopon
Morpheridine
Morphine
Morphine methobromide, morphine N-oxide and other pentavalent nitrogen
morphine derivatives
Myrophine
Nabilone
Nicomorphine
Noracymethadol
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Oripavine
Oxycodone
Oxymorphone
Pethidine
Phenadoxone
Phenampromide
Phenazocine
Phencyclidine
Phenomorphan
Phenoperidine
Piminodine
Piritramide
Proheptazine
Properidine
Racemethorphan
Racemoramide
Racemorphan
Remifentanil
Sufentanil
Thebacon
Thebaine
Tilidate
Trimeperidine
Zipeprol
4-Cyano-2-dimethylamino-4, 4-diphenylbutane
4-Cyano-1-methyl-4- phenylpiperidine
2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid

α -Methylphenethylhydroxylamine
1-Methyl-4-phenylpiperidine-4-carboxylic acid
4-Phenylpiperidine-4-carboxylic acid ethyl ester.

2. Any stereoisomeric form of a substance specified in paragraph 1, not being dextromethorphan or dextrorphan.
3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.
4. Any salt of a substance specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
6. The following substances and products —

Acetyldihydrocodeine
Amphetamine
Codeine
Dextropropoxyphene
Dihydrocodeine
Ethylmorphine (3-ethylmorphine)
Fenethylamine
Glutethimide
Lefetamine
Mecloqualone
Methaqualone
Methylamphetamine
Methylphenidate
Nicocodine
Nicodicodine (6-nicotinoyldihydrocodeine)
Norcodeine
Phenmetrazine
Pholcodine
Propiram
Quinalbarbitone.

7. Any stereoisomeric form of a substance specified in paragraph 6.
8. Any salt of a substance specified in paragraph 6 or 7.

9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.

SCHEDULE 3

Sections 8, 9, 12(7)(b),
18(2)(b), 20 and 22

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF
SECTIONS 12, 13 (EXCEPT TEMAZEPAM AND MIDAZOLAM), 14, 16, 20,
21, 22, 23 AND 24.

1. The following substances –
- (a) Benzphetamine
Buprenorphine
Cathine
Chlorphentermine
Diethylpropion
Ethchlorvynol
Ethinamate
Flunitrazepam
Mazindol
Mephentermine
Meprobamate
Methylphenobarbitone
Methyprylone
Midazolam
Pentazocine
Phendimetrazine
Phentermine
Pipradrol
Temazepam;
 - (b) any 5,5 disubstituted barbituric acid not being quinalbarbitone.
2. Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.
3. Any salt of a substance specified in paragraph 1 or 2.

4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

SCHEDULE 4

Sections 3, 8, 13(1), 14, and 20(3)

PART I

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF SECTIONS 20, 21, 23 AND 24

1. The following substances and products –

Alprazolam
Aminorex
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
N-Ethylamphetamine
Ethyl loflazepate
Fencamfamin
Fenproporex
Fludiazepam
Flurazepam

Halazepam
Haloxazolam
4-Hydroxy-n-Butyric Acid – also known as
Gammahydroxy-butyrate (GHB)
Ketamine
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Mefenorex
Mesocarb
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Pinazepam
Prazepam
Pyrovalerone
Tetrazepam
Triazolam
Zolpidem.

2. Any stereoisomeric form of a substance specified in paragraph 1.
3. Any salt of a substance specified in paragraph 1 or 2.
4. Any preparation or other product containing a substance of product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

PART II

CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT; EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM IMPORTATION AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM OF A MEDICINAL PRODUCT FOR PERSONAL ADMINISTRATION; AND SUBJECT TO THE REQUIREMENTS OF SECTIONS 20, 21, 23, AND 24.

1. The following substances and products –

5 α -Androstane-3,17-diol

Androst-4-ene-3,17-diol

1-Androstenediol

1-Androstenedione

4-Androstene-3, 17 dione

5-Androstenedione

5-Androstene-3, 17 diol

Atamestane

Bolandioli

Bolasterone

Bolazine

Boldenone

Boldione

Bolenol

Bolmantalate

4-Chloromethandienone

Clostebol

Danazol

Desoxymethyltestosterone

Drostanolone

Enestebol

Eptiostanol

Ethyloestrenol

Fluoxymesterone

Formebolone

Furazabol

Gestrinone

3-Hydroxy-5 α -androstan-17-one

Mebolazine

Mepitiostane

Mestanolone

Mesterolone

Methandienone

Methandriol

Methenolone

Methyltestosterone

Metribolone

Mibolerone

Nandrolone
19-Norandrostenedione
19-Nor-5-Androstene-3, 17 diol
19-Norandrosterone
19-Nor-4-Androstene-3, 17 dione
Norethandrolone
19-Noretiocholanolone
Norboletone
Norclostebol
Norclostebol
Ovandrotone
Oxabolone
Oxadrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
Prostanozol
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone
Tetrahydrogestrinone
Thiomesterone
Trenbolone.

2. Any compound (not being Trilostane or a compound specified in paragraph 1 of this Part) structurally derived from 17-hydroxyandrostane-3-one or from 17-hydroxyestrane-3-one by modification in any of the following ways –
- (a) by further substitution at position 17 by a methyl or ethyl group;
 - (b) by substitution to any extent at one or more positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
 - (c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than ethylenic bonds in any one carbocyclic ring; or
 - (d) by fusion of ring A with a heterocyclic system.

3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part.
4. The following substances-
 - Chorionic gonadotrophin (HCG)
 - Clenbuterol
 - Non-human chorionic gonadotrophin (HCG)
 - Somatotropin
 - Somatrem
 - Somatropin
 - Zeranol
 - Zilpaterol.
5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part.
6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part.
7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part, not being a preparation specified in Schedule 5.